Table I.
Participants after exclusion of people with venous thromboembolism prior to registry entry or who had a recurrence during anticoagulant therapy.
| Autoimmune disease | No autoimmune disease | |
|---|---|---|
| Patients, N | 1305 | 50608 |
| Inflammatory bowel disease, n (%) | 275 (21) | |
| Systemic lupus erythematosus, n (%) | 97 (7) | |
| Behçet’s disease, n (%) | 18 (1) | |
| Temporal arteritis, n (%) | 74 (6) | |
| Other vasculitis, n (%) | 148 (11) | |
| Rheumatoid arthritis | 459 (35) | |
| Ankylosing spondylitis | 42 (4) | |
| Polymyalgia rheumatica | 225 (17) | |
| Clinical characteristics | ||
| Age, years, mean (SD) | 66 (17) | 68 (18) |
| Male gender, n (%) | 477 (36) | 24391 (48) |
| Anti‐phospholipid antibodies | 11 (1) | 26 (0) |
| Initial VTE presentation | ||
| DVT only, n (%) | 505 (39) | 20491 (40) |
| Pulmonary embolism* | 800 (61) | 30117 (60) |
| VTE type | ||
| Unprovoked | 742 (57) | 23021 (45) |
| Active cancer | 143 (11) | 11117 (22) |
| Other provoking factors | 420 (32) | 16470 (33) |
DVT, deep venous thrombosis; SD, standard deviation; VTE, venous thromboembolism.
*
With or without DVT.